ENCell Co., Ltd. (KOSDAQ:456070)

Market Cap	121.68B -25.1%
Revenue (ttm)	5.26B -27.1%
Net Income	-16.11B
EPS	-1,482.14
Shares Out	11.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,142
Average Volume	115,209
Open	11,340
Previous Close	11,460
Day's Range	10,910 - 11,560
52-Week Range	10,000 - 20,950
Beta	n/a
RSI	21.52
Earnings Date	n/a

About ENCell

Encell Co. Ltd. engages in the research, development, and manufacture of biopharmaceuticals. It provides customized pharmaceutical development services, from early development stage to approval stage. The company was founded in February 2018 and is headquartered in Seoul, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 456070

Financial Performance

In 2025, ENCell's revenue was 5.26 billion, a decrease of -27.06% compared to the previous year's 7.21 billion. Losses were -16.11 billion, 5.90% more than in 2024.